{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:32:13Z","timestamp":1791894733874,"version":"4.3.4"},"reference-count":95,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T00:00:00Z","timestamp":1524096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of clinically aggressive diseases associated with poor outcome. Despite progress in the last several years, resulting in a deeper understanding of the natural history and biology of PTCL based on molecular profiling and next-generation sequencing, there is a need for improvement in efficacy of chemotherapeutic regimens for newly diagnosed patients. Treatment in the front-line setting is most often cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like regimens, which are associated with a high failure rate and frequent relapses. Trials evaluating intensive chemotherapy have resulted in variable success in prolonging event-free survival, but overall survival has remained unchanged. Furthermore, this strategy is limited to patients who are in complete remission after initial anthracycline-based chemotherapy. Many patients are ineligible for hematopoietic stem cell transplantation because of age or failure to achieve remission. For relapsed disease, advances have been made in the therapeutic arsenal for PTCL. New drugs investigated in phase II studies have achieved response rates between 10% and 30%. However, to date the identification of new therapies has been largely empiric, and long-term remissions are the exception to the rule. Current patient outcomes suggest the need for the identification and development of active and biologically rational therapies to improve disease management and to extend the duration of response with iterative biomarker evaluation. This review covers the management of PTCL and focuses on new agents and therapeutic combinations, based on a better understanding of biology and pathogenesis of the disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Recent progress in understanding of the biology and pathogenesis of peripheral T-cell lymphoma has led to the emergence of new drugs. Unfortunately, this has not been met with similar advances in outcome improvement. Anthracycline-containing regimens, mostly cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), are considered the standard of care, although the best first-line approach remains to be defined. In the relapsed and refractory settings, several new agents achieved response rates between 10% and 30%, although these drugs do not significantly affect survival rates. Therapeutic options based on better molecular characterization of various histological types and combinations with the CHOP regimen or synergic combinations of new drugs may lead to better outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0524","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T15:55:15Z","timestamp":1524153315000},"page":"1039-1053","source":"Crossref","is-referenced-by-count":47,"title":["Recent Advances in the Treatment of Peripheral T-Cell Lymphoma"],"prefix":"10.1093","volume":"23","author":[{"given":"Kamel","family":"Laribi","sequence":"first","affiliation":[{"name":"Department of Hematology, Centre Hospitalier Le Mans, Le Mans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustapha","family":"Alani","sequence":"additional","affiliation":[{"name":"Department of Hematology, Centre Hospitalier Le Mans, Le Mans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Truong","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Centre Hospitalier Le Mans, Le Mans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Baugier de Materre","sequence":"additional","affiliation":[{"name":"Geriatric Department, Rothschild Hospital, Assistance Publique H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,4,19]]},"reference":[{"key":"2021122511121435000_onco12448-bib-0001","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0002","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0003","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.11173","article-title":"The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing\/refractory peripheral T-cell lymphoma","volume":"92","author":"Rodr\u00edguez","year":"2007","journal-title":"Haematologica"},{"key":"2021122511121435000_onco12448-bib-0004","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0005","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/path.945","article-title":"p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome","volume":"195","author":"Pescarmona","year":"2001","journal-title":"J Pathol"},{"key":"2021122511121435000_onco12448-bib-0006","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrclinonc.2011.51","article-title":"Hematology: Relapsed and refractory PTCL\u2013into the therapeutic abyss","volume":"8","author":"Foss","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0007","doi-asserted-by":"crossref","first-page":"623924","DOI":"10.5402\/2011\/623924","article-title":"A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma","volume":"2011","author":"Abouyabis","year":"2011","journal-title":"ISRN Hematol"},{"key":"2021122511121435000_onco12448-bib-0008","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK\u2212 anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0009","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0010","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: A report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0011","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","article-title":"Two-weekly or 3 weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0012","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.critrevonc.2013.08.016","article-title":"Peripheral T-cell lymphoma: The role of hematopoietic stem cell transplantation","volume":"89","author":"Gkotzamanidou","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122511121435000_onco12448-bib-0013","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.11173","article-title":"The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing\/refractory peripheral T-cell lymphoma","volume":"92","author":"Rodr\u00edguez","year":"2007","journal-title":"Haematologica"},{"key":"2021122511121435000_onco12448-bib-0014","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: Results of a prospective multicenter study","volume":"27","author":"R\u00fcdiger","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0015","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"key":"2021122511121435000_onco12448-bib-0016","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122511121435000_onco12448-bib-0017","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a large US multicenter cohort: Prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122511121435000_onco12448-bib-0018","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0019","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbmt.2013.01.006","article-title":"Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma","volume":"19","author":"Kanakry","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122511121435000_onco12448-bib-0020","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","article-title":"Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: A retrospective study from the lymphoma working party of the European Group for Blood and Marrow Transplantation","volume":"27","author":"Kyriakou","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0021","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1023\/A:1008200307625","article-title":"Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification","volume":"8","author":"Ascani","year":"1997","journal-title":"Ann Oncol"},{"key":"2021122511121435000_onco12448-bib-0022","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/1042819021000030054","article-title":"Peripheral T-cell lymphomas: Clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification","volume":"44","author":"Arrowsmith","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"2021122511121435000_onco12448-bib-0023","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1182\/blood.V75.2.434.434","article-title":"Peripheral T-cell lymphoma associated with hemophagocytic syndrome","volume":"75","author":"Falini","year":"1990","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0024","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"2021122511121435000_onco12448-bib-0025","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","article-title":"ESMO Guidelines Committee. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d'Amore","year":"2015","journal-title":"Ann Oncol"},{"key":"2021122511121435000_onco12448-bib-0026","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: A study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0027","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cncr.30416","article-title":"A prospective cohort study of patients with peripheral T-cell lymphoma in the United States","volume":"123","author":"Carson","year":"2017","journal-title":"Cancer"},{"key":"2021122511121435000_onco12448-bib-0028","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cncr.27733","article-title":"Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350","volume":"119","author":"Mahadevan","year":"2013","journal-title":"Cancer"},{"key":"2021122511121435000_onco12448-bib-0029","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: Spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphome: The Royal Marsden Hospital experience","volume":"92","author":"Arkenau","year":"2007","journal-title":"Hematologica"},{"key":"2021122511121435000_onco12448-bib-0031","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbmt.2008.04.004","article-title":"Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: The Stanford experience","volume":"14","author":"Chen","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122511121435000_onco12448-bib-0032","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0033","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.bmt.1705752","article-title":"The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: A BSBMT and ABMTRR study","volume":"40","author":"Feyler","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"2021122511121435000_onco12448-bib-0034","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0035","doi-asserted-by":"crossref","first-page":"4882A","DOI":"10.1182\/blood.V116.21.4882.4882","article-title":"Pralatrexate is effective as second-line treatment following cyclophosphamide\/doxorubicin\/vincristine\/prednisone (CHOP) failure in patients with relapsed or refractory peripheral T-Cell lymphoma (PTCL)","volume":"116","author":"Shustov","year":"2010","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0036","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-cell lymphoma","volume":"366","author":"Couronn\u00e9","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122511121435000_onco12448-bib-0037","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"key":"2021122511121435000_onco12448-bib-0038","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer Cell"},{"key":"2021122511121435000_onco12448-bib-0039","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood."},{"key":"2021122511121435000_onco12448-bib-0040","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0041","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0042","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J Hematol Oncol"},{"key":"2021122511121435000_onco12448-bib-0043","author":"National Comprehensive Cancer Network","year":"2016"},{"key":"2021122511121435000_onco12448-bib-0044","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0045","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0046","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0047","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0048","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0049","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/S2352-3026(15)00023-X","article-title":"Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: A non-randomised, phase 1b\/2 study","volume":"2","author":"Dupuis","year":"2015","journal-title":"Lancet Haematol"},{"key":"2021122511121435000_onco12448-bib-0050","doi-asserted-by":"crossref","first-page":"1824A","DOI":"10.1182\/blood.V128.22.1824.1824","article-title":"The pralatrexate-romidepsin doublet: A well tolerated and highly effective combination for patients with relapsed or refractory peripheral T-cell lymphoma","volume":"128","author":"Amengual","year":"2016","journal-title":"Blood"},{"issue":"suppl 15","key":"2021122511121435000_onco12448-bib-0051","doi-asserted-by":"crossref","first-page":"8521A","DOI":"10.1200\/jco.2015.33.15_suppl.8521","article-title":"A phase I\/II trial of the combination of romidepsin and lenalidomide in patients with relapsed\/refractory lymphoma and myeloma: Activity in T-cell lymphoma","volume":"33","author":"Mehta-Shah","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0052","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1080\/10428194.2016.1276287","article-title":"A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma","volume":"58","author":"Holkova","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2021122511121435000_onco12448-bib-0053","doi-asserted-by":"crossref","first-page":"2991A","DOI":"10.1182\/blood.V128.22.2991.2991","article-title":"A phase Ib\/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed\/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas","volume":"128","author":"Mehta-Shah","year":"2016","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0054","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjh.13855","article-title":"A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): Final results from the T-cell consortium trial","volume":"172","author":"Advani","year":"2016","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2021122511121435000_onco12448-bib-0055","doi-asserted-by":"crossref","first-page":"818A","DOI":"10.1182\/blood.V130.Suppl_1.818.818","article-title":"Pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in previously untreated patients with peripheral T-cell lymphoma (PTCL): A phase 1 dose-escalation study","volume":"130","author":"Shustov","year":"2017","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0056","doi-asserted-by":"crossref","first-page":"253A","DOI":"10.1182\/blood.V126.23.253.253","article-title":"Safe and effective treatment of patients with peripheral T-cell lymphoma (PTCL) with the novel HDAC inhibitor, belinostat, in combination with CHOP: Results of the Bel-CHOP phase 1 trial","volume":"126","author":"Johnston","year":"2015","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0057","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: Results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0058","doi-asserted-by":"crossref","first-page":"2993A","DOI":"10.1182\/blood.V128.22.2993.2993","article-title":"Four-year survival and durability results of brentuximab vedotin in combination with CHp in the frontline treatment of patients with CD30-expressing peripheral t-Cell Lymphomas","volume":"128","author":"Fanale","year":"2016","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0059","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: The BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0060","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"key":"2021122511121435000_onco12448-bib-0061","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur J Cancer"},{"key":"2021122511121435000_onco12448-bib-0062","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0063","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","article-title":"Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial","volume":"48","author":"Kim","year":"2012","journal-title":"Eur J Cancer"},{"key":"2021122511121435000_onco12448-bib-0064","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0065","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: Results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0066","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2021122511121435000_onco12448-bib-0067","doi-asserted-by":"crossref","first-page":"7501A","DOI":"10.1200\/JCO.2016.34.15_suppl.7501","article-title":"A prospective, multicenter, randomized study of anti-CCR4 monoclonal antibody mogamulizumab (moga) vs investigator's choice (IC) in the treatment of patients (pts) with relapsed\/refractory (R\/R) adult T-cell leukemia-lymphoma (ATL)","volume":"34","author":"Phillips","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0068","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/modpathol.2012.211","article-title":"Differential expression of aurora-A kinase in T-cell lymphomas","volume":"26","author":"Kanagal-Shamanna","year":"2013","journal-title":"Mod Pathol"},{"key":"2021122511121435000_onco12448-bib-0069","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1200\/JCO.2014.60.6327","article-title":"Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108","volume":"33","author":"Barr","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0070","doi-asserted-by":"crossref","first-page":"4493A","DOI":"10.1182\/blood.V124.21.4493.4493","article-title":"The investigational Aurora A kinase inhibitor alisertib exhibits broad activity in preclinical models of T-cell lymphoma and is highly synergistic with romidepsin","volume":"124","author":"Zullo","year":"2014","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0071","doi-asserted-by":"crossref","first-page":"1744A","DOI":"10.1182\/blood.V124.21.1744.1744","article-title":"A phase I trial of alisertib plus romidepsin for relapsed\/refractory aggressive B- and T-cell lymphomas","volume":"124","author":"Fanale","year":"2014","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0072","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: Spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0073","doi-asserted-by":"crossref","first-page":"djt378","DOI":"10.1093\/jnci\/djt378","article-title":"Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients","volume":"106","author":"Gambacorti Passerini","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2021122511121435000_onco12448-bib-0074","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2021122511121435000_onco12448-bib-0075","doi-asserted-by":"crossref","first-page":"819A","DOI":"10.1182\/blood.V130.Suppl_1.819.819","article-title":"In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-\u03b4,\u03b3 inhibitor, in combination with romidepsin or bortezomib in relapsed\/refractory T-cell lymphoma","volume":"130","author":"Moskowitz","year":"2017","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0076","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0077","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma","volume":"46","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat Genet."},{"key":"2021122511121435000_onco12448-bib-0078","doi-asserted-by":"crossref","first-page":"4164A","DOI":"10.1182\/blood.V128.22.4164.4164","article-title":"Treatment with hypomethylating agent 5-azacytidine induces sustained response in angioimmunoblastic T cell lymphomas","volume":"128","author":"Delarue","year":"2016","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0079","doi-asserted-by":"crossref","first-page":"3011A","DOI":"10.1182\/blood.V128.22.3011.3011","article-title":"Clinical activity and safety of RP6530, a dual PI3K\u03b4\/\u03b3 inhibitor, in patients with advanced hematologic malignancies: Final analysis of a phase 1 multicenter study","volume":"128","author":"Carlo-Stella","year":"2016","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0080","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0081","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/onc.2012.347","article-title":"JAK\/STAT signaling in hematological malignancies","volume":"32","author":"Vainchenker","year":"2013","journal-title":"Oncogene"},{"key":"2021122511121435000_onco12448-bib-0082","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1038\/ncomms7025","article-title":"Activating mutations of STAT5B and STAT3 in lymphomas derived from \u03b3\u03b4-T or NK cells","volume":"6","author":"K\u00fc\u00e7\u00fck","year":"2015","journal-title":"Nat Commun"},{"key":"2021122511121435000_onco12448-bib-0083","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2008-10-185256","article-title":"Clinical differences between nasal and extranasal natural killer\/T-cell lymphoma: A study of 136 cases from the International Peripheral T-Cell Lymphoma Project","volume":"113","author":"Au","year":"2009","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0084","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1158\/1078-0432.CCR-08-2914","article-title":"Variable clinical presentations of nasal and Waldeyer ring natural killer\/T-cell lymphoma","volume":"15","author":"Li","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122511121435000_onco12448-bib-0085","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood.V89.12.4501","article-title":"Nonnasal lymphoma expressing the natural killer cell marker CD56: A clinicopathologic study of 49 cases of an uncommon aggressive neoplasm","volume":"89","author":"Chan","year":"1997","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0086","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1200\/JCO.2016.68.1619","article-title":"Treatments and outcomes of patients with extranodal natural killer\/T-cell lymphoma diagnosed between 2000 and 2013: A cooperative study in Japan","volume":"35","author":"Yamaguchi","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122511121435000_onco12448-bib-0087","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cam4.569","article-title":"Five-year analysis from phase 2 trial of \u201csandwich\u201d chemoradiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer\/T- cell lymphoma","volume":"5","author":"Zhang","year":"2016","journal-title":"Cancer Med"},{"issue":"suppl 1","key":"2021122511121435000_onco12448-bib-0088","first-page":"140A","article-title":"5-year follow-up of the SMILE phase II study for newly-diagnosed stage IV, relapsed or refractory extra-nodal NK\/T-cell lymphoma, nasal type","volume":"33","author":"Suzuki","year":"2015","journal-title":"Hematol Oncol"},{"key":"2021122511121435000_onco12448-bib-0089","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1158\/1078-0432.CCR-16-0153","article-title":"DDGP versus SMILE in newly diagnosed advanced natural killer\/T-cell lymphoma: A randomized controlled, multicenter, open-label study in China","volume":"22","author":"Li","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021122511121435000_onco12448-bib-0090","doi-asserted-by":"crossref","first-page":"35412","DOI":"10.18632\/oncotarget.8643","article-title":"Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK\/T-cell lymphoma","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"2021122511121435000_onco12448-bib-0091","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.bbmt.2015.05.003","article-title":"Consortium for Improving Survival of Lymphoma Study. Clinical outcomes and prognostic factors of up-front autologous stem cell transplantation in patients with extranodal natural killer\/T cell lymphoma","volume":"21","author":"Yhim","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122511121435000_onco12448-bib-0092","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"2021122511121435000_onco12448-bib-0093","doi-asserted-by":"crossref","first-page":"33035","DOI":"10.18632\/oncotarget.8847","article-title":"High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK\/T cell lymphoma patients","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"2021122511121435000_onco12448-bib-0094","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJMc1605684","article-title":"Targeting CD38 in refractory extranodal natural killer cell-T-cell lymphoma","volume":"375","author":"Hari","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122511121435000_onco12448-bib-0095","doi-asserted-by":"crossref","first-page":"254","DOI":"10.5045\/br.2015.50.4.254","article-title":"Complete remission in CD30-positive refractory extranodal NK\/T-cell lymphoma with brentuximab vedotin","volume":"50","author":"Kim","year":"2015","journal-title":"Blood Res"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0524","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0524","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/9\/1039\/41915542\/oncolo_23_9_1039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/9\/1039\/41915542\/oncolo_23_9_1039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T11:13:34Z","timestamp":1640430814000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/9\/1039\/6439679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,19]]},"references-count":95,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,4,19]]},"published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0524","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,9,1]]},"published":{"date-parts":[[2018,4,19]]}}}